Edition:
United States

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

24.62USD
16 Feb 2018
Change (% chg)

$0.03 (+0.12%)
Prev Close
$24.59
Open
$24.80
Day's High
$25.10
Day's Low
$23.79
Volume
105,100
Avg. Vol
183,029
52-wk High
$25.42
52-wk Low
$4.74

Select another date:

Mon, Jan 22 2018

BRIEF-Uniqure Receives Orphan Medicinal Product Designation In Europe For Amt-130 In Huntington’S Disease

* UNIQURE RECEIVES ORPHAN MEDICINAL PRODUCT DESIGNATION IN EUROPE FOR AMT-130 IN HUNTINGTON’S DISEASE Source text for Eikon: Further company coverage:

BRIEF-Uniqure Says As Of Dec 31 Co Had $159 Mln In Cash & Cash Equivalents

* UNIQURE PROVIDES YEAR-END 2017 CORPORATE UPDATE AND OUTLINES NEAR-TERM OBJECTIVES TO FURTHER DRIVE SHAREHOLDER VALUE

BRIEF-Uniqure Q3 loss per share $0.40

* Uniqure announces third quarter 2017 financial results and recent company progress

BRIEF-UniQure reports Q3 loss $0.40/shr

* UniQure announces third quarter 2017 financial results and recent company progress

BRIEF-Uniqure announces proposed public offering

* Uniqure NV - ‍ commenced an underwritten public offering of 5 million of its ordinary shares Source text for Eikon: Further company coverage:

BRIEF-uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX

* uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua) Source text for Eikon: Further company coverage:

BRIEF-Uniqure announces AMT-061 to enter pivotal study in 2018

* Uniqure announces Hemophilia B gene therapy program to enter pivotal study with FIX-Padua variant in 2018

BRIEF-Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease

* Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease Source text for Eikon: Further company coverage:

Select another date: